Key result
IV furosemide, isosorbide dinitrate, or both undergo RCT evaluation for 30-day hospital-free days in AHF.
Why the study?
The individual and combined effects of loop diuretics and vasodilators have never been directly compared during the initial emergency phase of acute heart failure, leaving optimal first-line treatment unknown.
Does early treatment with intravenous furosemide, intravenous isosorbide dinitrate, or their combination improve days alive and outside of hospital at 30 days in patients with suspected acute heart failure?
Population
1,041 patients with suspected acute heart failure across five Danish hospitals
Comparison
Intravenous furosemide vs intravenous isosorbide dinitrate vs both
Design
Pragmatic, multicenter, randomized, double-blinded, placebo-controlled trial
Follow-up
30 days
Authors
Loading...
This RCT will test early IV furosemide-ISDN in acute HF; extends post-stabilization data to hyperacute phase.
RCT (n=1,041)
Double-blind
1:1:1
Yes
Does early treatment with intravenous furosemide, intravenous isosorbide dinitrate, or their combination improve days alive and outside of hospital at 30 days in patients with suspected acute heart failure?
The DECONGEST-AHF trial will evaluate the individual and combined effects of early intravenous furosemide and isosorbide dinitrate in patients with acute heart failure.
Olesen et al. (2026) conducted an RCT in Acute heart failure (n=1,041). Intravenous furosemide, intravenous isosorbide dinitrate, or both vs. Placebo was evaluated on Days alive and outside of hospital at 30 days. Intravenous furosemide, isosorbide dinitrate, or their combination will be evaluated in 1,041 patients with acute heart failure for the primary outcome of days alive and out of hospital at 30 days.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: